Fennec Pharmaceuticals Inc (FENC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Fennec Pharmaceuticals Inc (FENC) has a cash flow conversion efficiency ratio of -0.333x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.49 Million) by net assets ($-4.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Fennec Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Fennec Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Fennec Pharmaceuticals Inc for a breakdown of total debt and financial obligations.
Fennec Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fennec Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Teamlease Services Limited
NSE:TEAMLEASE
|
0.046x |
|
Dogan Burda Dergi Yayincilik ve Pazarlama AS
IS:DOBUR
|
0.164x |
|
Datawalk SA
WAR:DAT
|
-1.044x |
|
GD Culture Group Limited
NASDAQ:GDC
|
-0.001x |
|
Trisul S.A
SA:TRIS3
|
-0.024x |
|
Churchill Capital Corp X Class A Ordinary Shares
NASDAQ:CCCX
|
-0.003x |
|
Foraco International SA
TO:FAR
|
0.106x |
|
GE Power India Limited
NSE:GEPIL
|
1.009x |
Annual Cash Flow Conversion Efficiency for Fennec Pharmaceuticals Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Fennec Pharmaceuticals Inc from 1999 to 2024. For the full company profile with market capitalisation and key ratios, see Fennec Pharmaceuticals Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-5.87 Million | $26.98 Million | -4.595x | -411.49% |
| 2023-12-31 | $-11.62 Million | $-17.14 Million | 1.475x | -79.02% |
| 2022-12-31 | $-2.57 Million | $-18.06 Million | 7.029x | +879.53% |
| 2021-12-31 | $15.77 Million | $-14.22 Million | -0.902x | -68.09% |
| 2020-12-31 | $29.07 Million | $-15.60 Million | -0.536x | +29.69% |
| 2019-12-31 | $11.88 Million | $-9.06 Million | -0.763x | -107.78% |
| 2018-12-31 | $21.31 Million | $-7.83 Million | -0.367x | -169.84% |
| 2017-12-31 | $26.76 Million | $-3.64 Million | -0.136x | +77.13% |
| 2016-12-31 | $3.57 Million | $-2.12 Million | -0.595x | +82.49% |
| 2015-12-31 | $548.00K | $-1.86 Million | -3.398x | -22.59% |
| 2014-12-31 | $613.00K | $-1.70 Million | -2.772x | -282.48% |
| 2013-12-31 | $-1.46 Million | $-2.21 Million | 1.519x | +151.48% |
| 2012-12-31 | $-4.96 Million | $-2.99 Million | 0.604x | -97.75% |
| 2011-12-31 | $-120.00K | $-3.23 Million | 26.883x | +6765.85% |
| 2010-12-31 | $-4.92 Million | $-1.93 Million | 0.392x | +103.39% |
| 2009-12-31 | $406.00K | $-4.69 Million | -11.547x | -226.17% |
| 2008-12-31 | $3.05 Million | $-10.81 Million | -3.540x | -276.50% |
| 2007-12-31 | $14.15 Million | $-13.30 Million | -0.940x | +47.07% |
| 2006-12-31 | $7.58 Million | $-13.47 Million | -1.777x | -190.61% |
| 2005-12-31 | $20.06 Million | $-12.26 Million | -0.611x | -236.82% |
| 2003-12-31 | $33.00 Million | $-5.99 Million | -0.181x | +48.85% |
| 2002-12-31 | $15.31 Million | $-5.43 Million | -0.355x | +33.18% |
| 2001-12-31 | $6.08 Million | $-3.23 Million | -0.531x | -93.96% |
| 2000-12-31 | $9.82 Million | $-2.69 Million | -0.274x | +98.95% |
| 1999-12-31 | $46.73K | $-1.22 Million | -26.189x | -- |
About Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly … Read more